middle.news
Recce Pharmaceuticals Hits 93% Efficacy in Phase II Trial of RECCE® 327 Gel
9:24am on Monday 17th of February, 2025 AEDT
•
Pharmaceuticals
Read Story
Recce Pharmaceuticals Hits 93% Efficacy in Phase II Trial of RECCE® 327 Gel
9:24am on Monday 17th of February, 2025 AEDT
Key Points
RECCE® 327 gel achieved 93% primary efficacy in Phase II trial for ABSSSI
Trial included patients with diabetic foot infections, showing rapid clinical response
Phase 3 registrational trials planned in Indonesia and Australia with interim analysis
No serious adverse events reported, confirming safety and tolerability
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Recce Pharmaceuticals (ASX:RCE)
OPEN ARTICLE